Literature DB >> 21564166

Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects, Dixon et al. 2008; request for publication of PR interval data.

G David Rudd, John-Kenneth Sake.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21564166      PMCID： PMC3099386          DOI： 10.1111/j.1365-2125.2010.03856.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  3 in total

1.  Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.

Authors:  Ruth Dixon; Sarah Job; Ruth Oliver; Debra Tompson; John G Wright; Kay Maltby; Ulrike Lorch; Jorg Taubel
Journal:  Br J Clin Pharmacol       Date:  2008-07-23       Impact factor: 4.335

2.  Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group.

Authors:  F Matsuo; D Bergen; E Faught; J A Messenheimer; A T Dren; G D Rudd; C G Lineberry
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

3.  Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine.

Authors:  Erik Saetre; Mikael Abdelnoor; Jan Peder Amlie; Morten Tossebro; Emilio Perucca; Erik Taubøll; Ole Gunnar Anfinsen; Jouko Isojärvi; Leif Gjerstad
Journal:  Epilepsia       Date:  2009-03-23       Impact factor: 5.864
  3 in total
  1 in total

1.  Concentration-response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent.

Authors:  Junzhen Wu; Kun Wang; Yuancheng Chen; Hong Yuan; Li Li; Jing Zhang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-13       Impact factor: 2.745
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.